Announcements
- Cosmo reports record 2022 financial results exceeding guidance, increased dividend by 10%, confirms 2023 guidance
- Cosmo Pharmaceuticals announces that Cosmo Intelligent Medical Devices – IMD Ltd, fully owned subsidiary of Cosmo Pharmaceuticals, and Medtronic to expand cooperation on GI Genius™
- Cosmo Pharmaceuticals reports record results for 2022, preliminary results exceeding guidance, increased dividend distribution and 2023 guidance
Key statistics
On Wednesday, Cosmo Pharmaceuticals NV (C43:BRN) closed at 53.77, 4.78% above its 52-week low of 51.32, set on Aug 03, 2022.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 53.77 |
---|---|
High | 53.77 |
Low | 53.77 |
Bid | -- |
Offer | -- |
Previous close | 53.77 |
Average volume | 104.00 |
---|---|
Shares outstanding | 17.54m |
Free float | 9.25m |
P/E (TTM) | 29.46 |
Market cap | 965.73m CHF |
EPS (TTM) | 1.87 CHF |
Annual div (ADY) | 0.9741 CHF |
---|---|
Annual div yield (ADY) | 1.81% |
Div ex-date | Jun 01 2022 |
Div pay-date | Jun 03 2022 |
Data delayed at least 15 minutes, as of Mar 22 2023.
More ▼